pyrroles has been researched along with u 62840 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chaudhary, KR; Deng, Y; Mei, SHJ; Petersen, TH; Stewart, DJ; Suen, CM; Taha, M | 1 |
| Chapman, RW; Chun, D; Cipolla, D; Corboz, MR; Gauani, H; Li, Z; Malinin, V; Perkins, WR; Plaunt, AJ | 1 |
2 other study(ies) available for pyrroles and u 62840
| Article | Year |
|---|---|
Efficacy of treprostinil in the SU5416-hypoxia model of severe pulmonary arterial hypertension: haemodynamic benefits are not associated with improvements in arterial remodelling.
Topics: Angiogenesis Inhibitors; Animals; Antihypertensive Agents; Epoprostenol; Hemodynamics; Hypertension, Pulmonary; Hypoxia; Indoles; Male; Protein Kinase Inhibitors; Pyrroles; Rats, Sprague-Dawley; Vascular Remodeling; Vasodilator Agents; Ventricular Function, Right | 2018 |
Treprostinil palmitil inhibits the hemodynamic and histopathological changes in the pulmonary vasculature and heart in an animal model of pulmonary arterial hypertension.
Topics: Administration, Inhalation; Administration, Oral; Animals; Collagen; Disease Models, Animal; Epoprostenol; Heart; Hemodynamics; Hypoxia; Indoles; Male; Myocardium; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Artery; Pyrroles; Rats, Sprague-Dawley; Sildenafil Citrate; Vascular Remodeling; Vasodilator Agents | 2022 |